Early deferasirox treatment in a patient with myelodysplastic syndrome results in a long-term reduction in transfusion requirements

Acta Haematologica

Volumn 121, Issue 1, 2009, Pages 19-20

  Capalbo, Silvana ^a   Spinosa, Giuseppina ^a   Franzese, Maria Grazia ^a   Palumbo, Gaetano ^a  

^a Azienda Ospedaliero Universitaria   (Italy)

Author keywords

Deferasirox; Iron chelation; Myelodysplastic syndrome

Indexed keywords

DEFERASIROX; DEFEROXAMINE; FERRITIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ABSENCE OF SIDE EFFECTS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; ERYTHROCYTE TRANSFUSION; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON CHELATION; IRON OVERLOAD; LETTER; MYELODYSPLASTIC SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PRIORITY JOURNAL;

AGED; BENZOIC ACIDS; BLOOD TRANSFUSION; FEMALE; HEMOGLOBINS; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MYELODYSPLASTIC SYNDROMES; PRIMARY MYELOFIBROSIS; TREATMENT OUTCOME; TRIAZOLES;

EID: 61849089299     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000209206     Document Type: Letter

References (10)

1. Messa E, Cilloni D, Messa F, Arruga F, Roetto A, Saglio G: Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol 2008; 20: 70-74.
2. Malcovati L, Della Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, Passamonti F, Arcaini L, Maffioli M, Bernasconi P, Lazzarino M, Cazzola M: Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005; 23: 7594-7603.
3. Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Aleya EP, Soiffer RJ, Antin JH: Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109: 4586-4588.
4. Altes A, Remacha AF, Sarda P, Baiget M, Sureda A, Martino R, Briones J, Brunet S, Canals C, Sierra J: Early clinical impact of iron overload in stem cell transplantation. A prospective study. Ann Hematol 2007; 86: 443-447.
5. Di Tucci AA, Murru R, Alberti D, Rabault B, Deplano S, Angelucci E: Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade - , ICL670). Eur J Haematol 2007; 78: 540-542.
6. Jensen PD, Heickendorff L, Pedersen B, Bendix- Hansen K, Jensen FT, Christensen T, Boesen AM, Ellegaard J: The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996; 94: 288-299.
7. Smeets ME, Vreugdenhil G, Holdrinet RS: Improvement of erythropoiesis during treatment with deferiprone in a patient with myelofibrosis and transfusional hemosiderosis. Am J Haematol 1996; 51: 243-244.
8. Vreugdenhil G, Smeets M, Feederls RA, Van Eijk HG: Iron chelators may enhance erythropoiesis by increasing iron delivery to haematopoietic tissue and erythropoietin response in iron-loading anaemia. Acta Haematol 1993; 89: 57-60.
9. Camaschella C, Campanella A, De Falco L, Boschetto L, Merlini R, Silvestri L, Levi S, Iolascon A: The human counterpart of zebrafish shiraz shows sideroblastic-like microcytic anemia and iron overload. Blood 2007; 110: 1353-1358.
10. Cappellini MD: Exjade (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion. Ther Clin Risk Manag 2007; 3: 291-299.